Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Nitric oxide may inhibit neointimal hyperplasia by decreasing isopeptidase T levels and activity in the vasculature.

Tsihlis ND, Kapadia MR, Vavra AK, Flannery WD, Oustwani CS, Jiang Q, Kibbe MR.

J Vasc Surg. 2013 Jul;58(1):179-86. doi: 10.1016/j.jvs.2012.10.066. Epub 2013 Jan 30.

2.

Nitric oxide differentially affects proteasome activator 28 after arterial injury in type 1 and type 2 diabetic rats.

Tsihlis ND, Rodriguez MP, Jiang Q, Schwartz A, Flynn ME, Vercammen JM, Kibbe MR.

J Surg Res. 2016 May 15;202(2):413-21. doi: 10.1016/j.jss.2016.01.030. Epub 2016 Jan 30.

3.

Nitric oxide inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by increasing the ubiquitination and degradation of UbcH10.

Tsihlis ND, Oustwani CS, Vavra AK, Jiang Q, Keefer LK, Kibbe MR.

Cell Biochem Biophys. 2011 Jun;60(1-2):89-97. doi: 10.1007/s12013-011-9179-3.

PMID:
21448667
4.

Nitric oxide decreases activity and levels of the 11S proteasome activator PA28 in the vasculature.

Tsihlis ND, Kapadia MR, Vavra AK, Jiang Q, Fu B, Martinez J, Kibbe MR.

Nitric Oxide. 2012 Jun 30;27(1):50-8. doi: 10.1016/j.niox.2012.04.006. Epub 2012 Apr 24.

PMID:
22561112
5.

New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of MMP-9.

Lee CS, Kwon YW, Yang HM, Kim SH, Kim TY, Hur J, Park KW, Cho HJ, Kang HJ, Park YB, Kim HS.

Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):472-9. doi: 10.1161/ATVBAHA.108.176230. Epub 2009 Feb 5.

6.

Nitric oxide and nanotechnology: a novel approach to inhibit neointimal hyperplasia.

Kapadia MR, Chow LW, Tsihlis ND, Ahanchi SS, Eng JW, Murar J, Martinez J, Popowich DA, Jiang Q, Hrabie JA, Saavedra JE, Keefer LK, Hulvat JF, Stupp SI, Kibbe MR.

J Vasc Surg. 2008 Jan;47(1):173-82. doi: 10.1016/j.jvs.2007.09.005.

7.

Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome.

Ahanchi SS, Varu VN, Tsihlis ND, Martinez J, Pearce CG, Kapadia MR, Jiang Q, Saavedra JE, Keefer LK, Hrabie JA, Kibbe MR.

Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2388-98. doi: 10.1152/ajpheart.00185.2008. Epub 2008 Oct 17.

8.

Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction.

Kim SY, Kwon YW, Jung IL, Sung JH, Park SG.

Cardiovasc Res. 2011 Nov 1;92(2):307-16. doi: 10.1093/cvr/cvr219. Epub 2011 Aug 11.

PMID:
21840882
9.

Blockade of the Ras-extracellular signal-regulated kinase 1/2 pathway is involved in smooth muscle 22 alpha-mediated suppression of vascular smooth muscle cell proliferation and neointima hyperplasia.

Dong LH, Wen JK, Liu G, McNutt MA, Miao SB, Gao R, Zheng B, Zhang H, Han M.

Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):683-91. doi: 10.1161/ATVBAHA.109.200501. Epub 2010 Feb 5.

10.

Inhibition of neointimal hyperplasia in the rat carotid artery injury model by a HMGB1 inhibitor.

Chen J, Zhang J, Xu L, Xu C, Chen S, Yang J, Jiang H.

Atherosclerosis. 2012 Oct;224(2):332-9. doi: 10.1016/j.atherosclerosis.2012.07.020. Epub 2012 Jul 24.

PMID:
22857898
11.

AMPKα2 deletion exacerbates neointima formation by upregulating Skp2 in vascular smooth muscle cells.

Song P, Wang S, He C, Wang S, Liang B, Viollet B, Zou MH.

Circ Res. 2011 Nov 11;109(11):1230-9. doi: 10.1161/CIRCRESAHA.111.250423. Epub 2011 Oct 6.

12.

Arginase promotes neointima formation in rat injured carotid arteries.

Peyton KJ, Ensenat D, Azam MA, Keswani AN, Kannan S, Liu XM, Wang H, Tulis DA, Durante W.

Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):488-94. doi: 10.1161/ATVBAHA.108.183392. Epub 2009 Jan 22.

13.

The induction of yes-associated protein expression after arterial injury is crucial for smooth muscle phenotypic modulation and neointima formation.

Wang X, Hu G, Gao X, Wang Y, Zhang W, Harmon EY, Zhi X, Xu Z, Lennartz MR, Barroso M, Trebak M, Chen C, Zhou J.

Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2662-9. doi: 10.1161/ATVBAHA.112.254730. Epub 2012 Aug 23.

14.

Activation of NAD(P)H:quinone oxidoreductase 1 prevents arterial restenosis by suppressing vascular smooth muscle cell proliferation.

Kim SY, Jeoung NH, Oh CJ, Choi YK, Lee HJ, Kim HJ, Kim JY, Hwang JH, Tadi S, Yim YH, Lee KU, Park KG, Huh S, Min KN, Jeong KH, Park MG, Kwak TH, Kweon GR, Inukai K, Shong M, Lee IK.

Circ Res. 2009 Apr 10;104(7):842-50. doi: 10.1161/CIRCRESAHA.108.189837. Epub 2009 Feb 19.

16.

Nitric oxide regulates the 26S proteasome in vascular smooth muscle cells.

Kapadia MR, Eng JW, Jiang Q, Stoyanovsky DA, Kibbe MR.

Nitric Oxide. 2009 Jun;20(4):279-88. doi: 10.1016/j.niox.2009.02.005. Epub 2009 Feb 20.

PMID:
19233305
17.

Nitric oxide prevents aortic neointimal hyperplasia by controlling macrophage polarization.

Lavin B, Gómez M, Pello OM, Castejon B, Piedras MJ, Saura M, Zaragoza C.

Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1739-46. doi: 10.1161/ATVBAHA.114.303866. Epub 2014 Jun 12.

18.

Downregulation of quinone reductase 2 attenuates vascular smooth muscle cells proliferation and neointimal formation in balloon injured rat carotid artery.

Zhang XW, Wang Y, Cai JB, Hou XF, Wang HG, Zou JG, Cao KJ.

Cell Physiol Biochem. 2012;29(3-4):453-62. doi: 10.1159/000338499. Epub 2012 Apr 3.

19.

The effect of insulin to decrease neointimal growth after arterial injury is endothelial nitric oxide synthase-dependent.

Guo J, Breen DM, Pereira TJ, Dalvi PS, Zhang H, Mori Y, Ghanim H, Tumiati L, Fantus IG, Bendeck MP, Dandona P, Rao V, Dolinsky VW, Heximer SP, Giacca A.

Atherosclerosis. 2015 Jul;241(1):111-20. doi: 10.1016/j.atherosclerosis.2015.04.799. Epub 2015 Apr 25.

PMID:
25974101
20.

CTP synthase 1, a smooth muscle-sensitive therapeutic target for effective vascular repair.

Tang R, Cui XB, Wang JN, Chen SY.

Arterioscler Thromb Vasc Biol. 2013 Oct;33(10):2336-44. doi: 10.1161/ATVBAHA.113.301561. Epub 2013 Sep 5.

Supplemental Content

Support Center